Jefferies analyst Roger Song initiated coverage of Zenas BioPharma with a Buy rating and $35 price target Zenas is a late clinical stage biotech focused on inflammation and immunology-directed opportunities, the analyst tells investors in a research note. The firm says the company’s lead asset is “first-in-class” obexelimab with a differentiated inhibitory mechanism of action for various B-cell driven autoimmune diseases.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO: